In explaining the rationale behind the study, Tang and colleagues pointed out that despite the lack of level 1 evidence, MDT ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 ...

Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation ...

Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.

Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high risk ...

DelveInsight's PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...